|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.024 - 0.025|
|52 Week Range||0.024 - 0.025|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
LONDON, UK / ACCESSWIRE / December 12, 2017 / Prima BioMed has changed its name to Immutep Limited (NASDAQ: PBMD) following shareholder approval in November. It reported an encouraging 33% preliminary ...
LONDON, UK / ACCESSWIRE / October 2, 2017 / Data presented at the European Society for Medical Oncology (ESMO) Congress by third parties has positive implications for Prima Biomed's (NASDAQ: PBMD) LAG3 ...
Prima Biomed Ltd. (PBMD) announced that a new clinical study, INSIGHT, on its lead candidate IMP321 has received regulatory approval for initiation